公开(公告)号：US10286086B2

公开(公告)日：2019-05-14

申请号：US15319840

申请日：2015-06-19

Applicant: ModernaTX, Inc.

Inventor： Atanu Roy ,  Christopher R. Conlee ,  Antonin De Fougerolles ,  Andrew W. Fraley ,  Gabor Butora ,  Matthew Stanton

IPC: A61K48/00 ,  C07F9/6558 ,  C07H19/06 ,  C07H19/16 ,  C12N15/11 ,  C12N15/67 ,  C07H21/02 ,  C07F9/6561 ,  C07D405/04 ,  C07D239/54 ,  C07H19/067 ,  C07H19/10 ,  C07H19/14 ,  C07H19/167 ,  C07H19/20 ,  C07H19/23 ,  C07D473/16 ,  C07D473/18 ,  C07D473/30 ,  C07D473/34 ,  C07D473/38 ,  C07D473/40 ,  C07D487/04 ,  C07D487/16 ,  C07D498/22 ,  C12N15/87

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

公开(公告)号：US12109274B2

公开(公告)日：2024-10-08

申请号：US15760686

申请日：2016-09-19

Applicant: ModernaTX, Inc.

Inventor： Gabor Butora ,  Andrew W. Fraley ,  Edward John Miracco ,  Jennifer Nelson ,  Amy Rhoden Smith ,  Matthew Stanton ,  Brian R. Fritz

IPC: A61K48/00 ,  C07F9/6558 ,  C07F9/6561 ,  C07H21/02 ,  C12N15/67

CPC classification number: A61K48/0066 ,  C07F9/65586 ,  C07F9/65616 ,  C07H21/02 ,  C12N15/67

Abstract: The invention features polynucleotides encoding a polypeptide including a 3′-stabilizing region and having increased stability compared to wild-type polynucleotides.

公开(公告)号：US09751925B2

公开(公告)日：2017-09-05

申请号：US14960031

申请日：2015-12-04

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  William Joseph Issa ,  Edward John Miracco ,  Jennifer Nelson ,  John Reynders ,  Matthew Stanton

IPC: C07K14/535 ,  C12P19/34 ,  C07K14/505 ,  C12N9/00 ,  C12N9/02

CPC classification number: C07K14/535 ,  A61K48/005 ,  C07K14/505 ,  C12N9/0069 ,  C12P19/34 ,  C12P21/02 ,  C12Y113/12007

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.